ME02202B - Jedinjenja pirolopirimidina kao inhibitori cdk4/6 - Google Patents

Jedinjenja pirolopirimidina kao inhibitori cdk4/6

Info

Publication number
ME02202B
ME02202B MEP-2015-157A MEP15715A ME02202B ME 02202 B ME02202 B ME 02202B ME P15715 A MEP15715 A ME P15715A ME 02202 B ME02202 B ME 02202B
Authority
ME
Montenegro
Prior art keywords
pyridin
pyrrolo
ylamino
diaza
cyclopentyl
Prior art date
Application number
MEP-2015-157A
Other languages
English (en)
Inventor
Yaping Wang
Christopher Thomas Brain
Young Shin Cho
John William Giraldes
Bharat Lagu
Julian Levell
Michael LUZZIO
Lawrence Blas Perez
Fan Yang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ME02202B publication Critical patent/ME02202B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Claims (25)

1. Jedinjenje prema formuli (I)naznačen time, što:R1 predstavlja C3-7alkil; C4-7 cikloalkil po slobodnom izboru supstituisan sa jednim ili više supstituenta koji su odabrani iz grupe koju čine C1-6alkil i OH; fenil po slobodnom izboru supstituisan jednim supstitutentom koji je odabran iz grupe koju čine C1-6 alkil, C(CH3)2CN, i OH; piperidinil po slobodnom izboru supstituisan sa jednom ciklopropil grupom ili C1-6 alkilom; tetrahidropiranil po slobodnom izboru supstituisan sa jednom ciklopropil grupom ili C1-6 alkilom; ili biciklo[2.2.1]heptanil;gde A predstavlja CH ili N;gde R11 predstavlja vodonik ili C1-4 alkil;gde L predstavlja vezu, C(O), ili S(O)2;gde R2Y može da bude izabran iz grupe koju čineV je NH ili CH2;X je O ili CH2;W je O ili NH;gde m i n svaki za sebe predstavljaju 1, 2, ili 3 pod uslovom da m i n nisu oba 3;gde je svaka R2Y po slobodnom izboru supstituisana sa jednim do četiri supstituenata od kojih je svaki nezavisno odabran iz grupe koju čine: C1-3 alkil po slobodnom izboru substituisan sa jednim ili dva supstituenta od kojih je svaki nezavisno odabran iz grupe koju čine hidroksi, NH2, i -S-C1-3alkil; CD3; halo; okso; C1-3 haloalkil; hidroksi; NH2; dimetilamino; benzil; -C(O)-C1-3alkil po slobodnom izboru supstituisan sa jednim ili dva supstituenta od kojih je svaki odabran iz grupe koju čine NH2’ -SCH3 i NHC(O)CH3; - S(O)2-C1-4 alkil; i pirolidinil-C(O)-;gde R4 predstavlja, vodonik, deuterijum, ili C(R5)(R6)(R7); igde R5, R6, R7, R8, R9 i R10 svaki za sebe nezavisno predstavljaju H ili deuterijum; ili njena farmaceutski prihvatljiva so.
2.Jedinjenje formule (I-B) prema patentnom zahtevu 1, naznačen time, što L predstavlja vezu ili C(O); gde R2Y može da bude izabran iz grupe koju čine V je NH ili CH2; X je O ili CH2; W je O ili NH; gde m i n svaki za sebe nezavisno mogu da budu 1, 2, ili 3 pod uslovom da m i n m i n nisu oba 3; gde je svaka R2Y po slobodnom izboru supstituisana sa jednim do četiri supstituenata od kojih je svaki odabran iz grupe koju čine: C1-3 alkil po slobodnom izboru substituisan sa jednim ili dva supstituenta od kojih je svaki nezavisno odabran iz grupe koju čine hidroksi, NH2, i -S-C1-3alkil; CD3; C1-3 haloalkil; hidroksi; NH2; dimetilamino; benzil; -C(O)-C1-3alkil po slobodnom izboru supstituisan sa jednim ili dva supstituenta od kojih je svaki odabran iz grupe koju čine NH2’ -SCH3 i NHC(O)CH3; - S(O)2-C1-4 alkil; i pirolidinil-C(O)-; ili njena farmaceutski prihvatljiva so.
3. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što A predstavlja CH i R11 je vodonik; ili njena farmaceutski prihvatljiva so.
4. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što R4 predstavlja C(R5)(R6)(R7) i R5, R6, R7, R8, R9 i R10 mogu da predstavljaju vodonik, ili njenu farmaceutski prihvatljivu so.
5. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što R1 predstavlja C4-7 cikloalkil koji je po slobodnom izboru supstituisan jednom C1-6 alkil grupom, ili njena farmaceutski prihvatljiva so.
6. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što je R2Y nesupstituisana ili njena farmaceutski prihvatljiva so.
7. Jedinjenje prema bilo kojem od patentnih zahteva 1-5 naznačen time, što R2Y predstavlja ili od kojih je bilo koja po slobodnom izboru supstituisana C1-3alkilom, ili njena farmaceutski prihvatljiva so.
8. Jedinjenje prema bilo kojem od patentnih zahteva 1-5 naznačen time, što R2Y predstavlja koja je po slobodnom izboru supstituisana C1-3 alkilom, ili njena farmaceutski prihvatljiva so.
9. Jedinjenje formule (I-C) u kojoj: R1 predstavlja ciklobutil, ciklopentil, cikloheksil, cikloheptil, gde je svaka od njih po slobodnom izboru supstituisana sa jednom metil,etil, ili OH; gde A predstavlja CH ili N; L može da predstavlja vezu, -C(O)-, ili S(O)2-; gde R2Y može da bude jedna iz grupe koju čine ili gde je svaka R2Y po slobodnom izboru supstituisana jednim ili dva supstituenta koji su nezavisno odabrani iz grupe koju čine halogen, metil, etil, ili okso; gde V predstavlja NH ili CH2; gde R4 predstavlja vodonik, deuterijum, ili C(R5)(R6)(R7); i R5, R6, R7, R8, R9 i R10 svaki za sebe nezavisno predstavljaju H ili deuterijum; ili njena ili njena farmaceutski prihvatljiva so.
10. Jedinjenje prema patentnom zahtevu 9, naznačen time, što A predstavlja CH; ili njena farmaceutski prihvatljiva so.
11. Jedinjenje prema patentnom zahtevu 10 naznačen time, što L predstavlja vezu ili -C(O)- i gde R4 predstavlja CH3; i R8, R9 i R10 mogu da budu H; ili njena farmaceutski prihvatljiva so.
12. Jedinjenje prema patentnom zahtevu 11 naznačen time, što R1 predstavlja ciklopentil; ili njena farmaceutski prihvatljiva so.
13. Jedinjenje prema patentnom zahtevu 1, naznačen time, što može biti odabrano iz grupe koju čine: 2-(5-(2,6-Diazaspiro[3.3]heptan-2-karbonil)piridin-2-ilamino)-7-ciklopentil-N,N-dimetil-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-(4-terc-Butil-fenil)-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Cikloheptil-2-[5-(2,5-diaza-biciklo[2.2.1]heptan-2-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-8-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 2-(5-(2,7-diazaspiro[3.5]nonan-7-karbonil)piridin-2-ilamino)-7-cikloheptil-N,N-dimetil-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-ciklopentil-2-[5-(8-metil-3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; metilamid 7-Ciklopentil-2-[5-((S,S)-2,5-diaza-biciklo[2.2.1]heptan-2-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-(3-terc-Butil-fenil)-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 2-(5-((1R,5S)-3-oksa-7,9-diazabiciklo[3.3.1]nonan-9-karbonil)piridin-2-ilamino)-7-ciklopentil-N,N-dimetil-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-[4-(Cijano-dimetil-metil)-fenil]-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-8-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-((1S,6R)-3,9-diaza-biciklo[4.2.1]nonan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-3,9-diaza-biciklo[4.2.1]nonan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,6-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 7-ciklopentil-N,N-dimetil-2-(5-(5’-okso-8-azaspiro[biciklo[3.2.1]oktan-3,3’-pirolidin]-1’-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-Ciklopentil-2[5-(1-okso-heksahidro-pirolo[1,2-a]pirazin-2-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 7-ciklopentil-N,N-dimetil-2-(5-(2-okso-1-oksa-3,8-diazaspiro[4.5]dekan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-Ciklopentil-2-[5-((1S,6R)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 2-[5-(4-Okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7-fenil-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; i 7-cikloheksil-N,N-dimetil-2-(5-(4-okso-3,9-diazabiciklo[4.2.1]nonan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; ili njena farmaceutski prihvatljiva so.
14. Jedinjenje prema patentnom zahtevu 1, naznačen time, što može biti odabrano iz grupe koju čine: dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-((S,S)-2,5-diaza-biciklo[2.2.1]heptan-2-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-((1S,5S)-3,6-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklobutil-2-[5-((1S,6R)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Cikloheksil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)- piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-6-metil-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-4-metil-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,9-diaza-biciklo[3.3.1]nonan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 7-ciklopentil-N,N-dimetil-2-(5-(3-okso-1,4-diazabiciklo[3.2.2]nonan-4-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((1R,6S)-9-metil-4-okso-3,9-diazabiciklo[4.2.1]nonan -3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((3aS,6aR)-1-oksoheksahidropirolo[3,4-c]pirol-2(1H)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((3aR,6aS)-1-oksoheksahidropirolo[3,4-c]pirol-2(1H)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-cikloheptil-N,N-dimetil-2-(5-(cis-6-oksotetrahidro-1H-pirolo[3,4-c]piridin-5(6H,7H,7aH)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-(cis-6-oksotetrahidro-1H-pirolo[3,4-c]piridin-5(6H,7H,7aH)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((3aR,6aS)-5-metil-1-oksoheksahidropirolo[3,4-c]pirol-2(1H)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((1R,3r,5S)-2’-okso-8-azaspiro[biciklo[3.2.1]oktan-3,5’-oksazolidin]-3’-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-(2-okso-1-oksa-3,8-diazaspiro[4.6]undekan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-(2-okso-1-oksa-3,7-diazaspiro[4.5]dekan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamide; dimetilamid 7-Ciklopentil-2-[5-((S)-2-okso-1-oksa-3,7-diaza-spiro[4.5]dec-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; i dimetilamid 7-Ciklopentil-2-[5-((R)-2-okso-1-oksa-3,7-diaza-spiro[4.5]dec-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; ili njena farmaceutski prihvatljiva so.
15. Jedinjenje prema patentnom zahtevu 1, naznačen time, što 7-ciklopentil-N,N-dimetil-2-(5-((1R,6S)-9-metil-4-okso-3,9-diazabiciklo[4.2.1]nonan-3-il)piridin-2-ilamino)-7H-pirolo[2,32,3-d]pirimidin-6-karboksamid ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
16. Jedinjenje prema patentnom zahtevu 1, naznačen time, što dimetilamid 7-Ciklopentil-2-[5-(3,8-diazabiciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
17. Jedinjenje prema patentnom zahtevu 1, naznačen time, što dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline ima sledeću formulu ili njena farmaceutski prihvatljiva so.
18. Jedinjenje prema patentnom zahtevu 1, naznačen time, što metilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
19. Jedinjenje prema patentnom zahtevu 1, naznačen time, što metilamid 7-ciklopentil-2-[5-((1R,6S)-9-metil-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
20. Farmaceutska kompozicija koja obuhvata jedinjenje prema bilo kojem od predhodnih patentnih zahteva, ili njena farmaceutski prihvatljiva so, i farmaceutski prihvatljivi nosač ili ekscipijent.
21. Jedinjenje prema patentnom zahtevu 1 ili 9, za upotrebu u medicini.
22. .Jedinjenje prema patentnom zahtevu 1 ili 9, za upotrebu u lečenju raka.
23. Jedinjenje prema patentnom zahtevu 1 ili 9, za upotrebu u lečenju raka, naznačen time, što je odabrano iz grupe koju čine: mantle ćelijski limfom, multipli mijelom, rak dojke, ezofagealni kancer skvamoznih ćelija, liposarkom, T-ćelijski limfom, melanom, nesitnoćelijski rak pluća i rak pankreasa, folikularni karcinom štitaste žlezde, tumor mezenhimalnog porekla, fibrosarkom, rabdomiosarkom, tumor centralnog ili perifernog nervnog sistema, astrocitom, neuroblastom, gliom, švanom, melanom, seminom, teratokarcinom, osteosarkom, kseroderma pigmentozum, retinoblastom, keratoakatantom, i Kapošijev sarkom, karcinom bešike, dojke, debelog creva, bubrega, epidermis, jetre, pluća, ezofagusa (jednjaka), žučne kese, karcinom jajnika, pankreasa, stomaka, cerviksa, štitne žlezde, nosa, glave i jezika, prostate, i kože, leukemija, akutna limfocitna leukaemija, hronična limfocitna leukaemija, B-ćelijski limfom, difuzni krupnoćelijski B limfom, T-ćelijski limfom, Hodžkinov limfom, ne Hodžkinov limfom, limfom vlasastih ćelija, i Burkitov limfom, glioblastom multiforme, T ćelijski ALL, sarkomi i familijarni melanom.
24. Upotreba jedinjenja prema patentnom zahtevu 1 u proizvodnji leka za lečenje raka.
25. Jedinjenje formule (I) prema patentnom zahtevu 1, ili njena farmaceutski prihvatljiva so u kombinaciji sa jednim ili više drugih terapijskih sredstava za simultanu, odvojenu ili sekvencijalnu upotrebu u terapiji. EP 2 536 730 B1 REFERENCE KOJE SU NAVEDENE U OPISU Popis literature od strane podnosioca služi samo kao priručnik za čitaoca. Priručnik nije deo Evropske patent dokumentacije. Iako se posvećuje velika pažnja prevodu referenci, greške i propusti ne mogu biti izuzeti i EPO se odriče svake odgovornosti u tom smislu • WO 2007140222 A [0006] • WO 2009085185 A [0006] • WO 2008135232 A [0006] • US 20090203688 A [0006] • WO 2010020675 A [0134] [0267] [0274] • WO 2009067108 W [0260] • WO 2005097791 W [0279] • WO 2007040282 A [0303] • WO 2006137769 W [0362] • DE 102005030051 A1 [0638] [0650] [0670] Nepatentna literatura koja je navedena u opisu: • ORTEGA et al. Biochimica et Biophysica Acta-Reviews on Cancer, 2002, vol. 1602 (1), 73-87 [0002] [0003] [0004] • SHAPIRO. Journal of Clinical Oncology, 2006, vol. 24 (11), 1770-1783 [0002] [0003] • LUNDBERG et al. Molecular and Cellular Biology, 1998, vol. 18 (2), 753-761 [0002] • KAMB et al. Science, 1994, vol. 264 (5157), 436-440 [0002] [0004] • SHERR et al. Genes & Development, vol. 13 (12), 1501-1512 [0002] • AMIN et al. Archives of Pathology & Laboratory Medicine, 2003, vol. 127 (4), 424-431 [0003] • OUDAT et al. Modern Pathology, 2001, vol. 14 (1), 175A [0003] • BERGSAGEL et al. Immunological Reviews, 2003, vol. 194 (1), 96-104 [0003] • JIANG et al. Cancer Research, 1992, vol. 52 (10), 2980-2983 [0004] • AMOLD et al. Journal of Clinical Oncology, 2005 [0004] • SIRVENT et al. American Journal of Surgical Pathology, 2007, vol. 31 (10), 1476-1489 [0004] • BRAMBILLA et al. Journal of Pathology, 1999, vol. 188 (4), 351-360 [0004] • COWGILL et al. American Journal of Surgery, 2003, vol. 186 (3), 279-286 [0004] • GAZZERI et al. Oncogene, 1998, vol. 16 (4), 497-504 [0004] • DAILEY et al. Cytokine & Growth Factor Reviews, 2005, vol. 16 (2), 233-247 [0005] • ENGELMAN. Nature Reviews Cancer, 2009, vol. 9 (8), 550-562 [0005] • GARCIA-ECHEVERRIA. Purinergic Signalling, 2009, vol. 5 (1), 117-125 [0005] • GRAY-SCHOPFER et al. Cancer and Metastesis Reviews, 2005, vol. 24 (1), 165-183 [0005] • JOHN et al. Oncogene, 2009, vol. 28, S14-S23 [0005] • SHARMA et al. Nature Reviews Cancer, 2007, vol. 7 (3), 169-181 [0005] • MORIARTY K.J. et al. Bioorg Med Chem Lett, 2006, vol. 16, 5778-5783 [0006] • Remington’s Pharmaceutical Sciences. Mack Publishing Company, 1985 [0053] • STAHL; WERMUTH. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Wiley-VCH, 2002 [0053] • GREEN ; WUTTS. Protective Groups in Organic Synthesis [0114] • AMIN, H. M. ; MCDONNELL, T. J. ; MEDEIROS, L. J. ; RASSIDAKIS, G. Z. ; LEVENTAKI, V.; ; O’CONNOR, S. L. ; KEATING, M. J. ; LAI, R. Characterization of 4 mantle cell lymphoma cell lines – Establishment of an in vitro study model. Arch. Pathol. Lab. Med., 2003, vol. 127, 424-431 [0886]
MEP-2015-157A 2010-02-19 2011-02-17 Jedinjenja pirolopirimidina kao inhibitori cdk4/6 ME02202B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30624810P 2010-02-19 2010-02-19
US201161429372P 2011-01-03 2011-01-03
US201161429997P 2011-01-05 2011-01-05
EP11707115.9A EP2536730B1 (en) 2010-02-19 2011-02-17 Pyrrolopyrimidine compounds as inhibitors of cdk4/6
PCT/EP2011/052353 WO2011101409A1 (en) 2010-02-19 2011-02-17 Pyrrolopyrimidine compounds as inhibitors of cdk4/6

Publications (1)

Publication Number Publication Date
ME02202B true ME02202B (me) 2016-02-20

Family

ID=44201966

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-157A ME02202B (me) 2010-02-19 2011-02-17 Jedinjenja pirolopirimidina kao inhibitori cdk4/6

Country Status (38)

Country Link
US (2) US8957074B2 (me)
EP (1) EP2536730B1 (me)
JP (1) JP5788415B2 (me)
KR (1) KR101812357B1 (me)
CN (1) CN102918043B (me)
AR (1) AR080198A1 (me)
AU (1) AU2011217286B2 (me)
BR (1) BR112012020922B1 (me)
CA (1) CA2790637C (me)
CL (1) CL2012002270A1 (me)
DK (1) DK2536730T3 (me)
DO (1) DOP2012000225A (me)
EA (1) EA022355B1 (me)
EC (1) ECSP12012111A (me)
ES (1) ES2548532T3 (me)
GE (1) GEP20146146B (me)
HN (1) HN2012001744A (me)
HR (1) HRP20151071T1 (me)
IL (1) IL221520A (me)
MA (1) MA34066B1 (me)
ME (1) ME02202B (me)
MX (1) MX2012009613A (me)
NI (1) NI201200135A (me)
NZ (1) NZ601754A (me)
PE (1) PE20121815A1 (me)
PH (1) PH12012501649A1 (me)
PL (1) PL2536730T3 (me)
PT (1) PT2536730E (me)
RS (1) RS54263B1 (me)
SG (1) SG183218A1 (me)
SI (1) SI2536730T1 (me)
SM (1) SMT201500265B (me)
TN (1) TN2012000413A1 (me)
TW (1) TWI503322B (me)
UA (1) UA108369C2 (me)
UY (1) UY33227A (me)
WO (1) WO2011101409A1 (me)
ZA (1) ZA201206079B (me)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02461B (me) 2005-05-10 2017-02-20 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
SG10201805844QA (en) 2008-07-08 2018-08-30 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
CN102186856B (zh) 2008-08-22 2014-09-24 诺华股份有限公司 作为cdk抑制剂的吡咯并嘧啶化合物
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US20130035336A1 (en) * 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
AU2012279117A1 (en) 2011-07-01 2014-01-09 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
EP2831080B1 (en) 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
RU2019102203A (ru) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
HK1213044A1 (zh) 2012-08-03 2016-06-24 Foundation Medicine, Inc. 人乳头瘤病毒作为肿瘤预後的预测因子
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
SI2951183T1 (sl) 2013-01-29 2019-07-31 Aptinyx Inc. Spiro-laktam NMDA receptorski modulatorji in njihove uporabe
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP2967050A4 (en) 2013-03-15 2016-09-28 G1 Therapeutics Inc HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS
EP2968291B1 (en) 2013-03-15 2025-04-16 Pharmacosmos Holding A/S Hspc-sparing treatments for rb-positive abnormal cellular proliferation
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
ES2900829T3 (es) 2013-08-14 2022-03-18 Novartis Ag Terapia combinada para el tratamiento del cáncer
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9717735B2 (en) 2014-04-17 2017-08-01 G1 Therapeutics, Inc. Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
AU2015266492B2 (en) * 2014-05-28 2017-11-02 Fochon Pharmaceuticals, Ltd. Certain protein kinase inhibitors
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
MX2017003254A (es) * 2014-09-11 2017-10-12 Janssen Pharmaceutica Nv 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
AU2016228660B2 (en) * 2015-03-11 2020-05-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
MY198562A (en) 2015-11-03 2023-09-05 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
WO2017096323A1 (en) * 2015-12-02 2017-06-08 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2017193872A1 (en) * 2016-05-07 2017-11-16 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
CA3028751A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018026763A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX383650B (es) * 2016-08-01 2025-03-14 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
BR112019005526A2 (pt) 2016-10-20 2019-06-18 Pfizer agentes antiproliferativos para tratamento de pah
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
WO2018089518A1 (en) 2016-11-08 2018-05-17 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
CN110382495B (zh) 2016-12-16 2022-04-05 基石药业（苏州）有限公司 Cdk4/6抑制剂
AU2018205262A1 (en) 2017-01-06 2019-07-11 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN108794452B (zh) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
MX392531B (es) 2017-06-29 2025-03-24 G1 Therapeutics Inc Formas morficas de g1t38 y metodos de preparacion de las mismas.
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
MA51846A (fr) * 2018-02-15 2021-04-21 Nuvation Bio Inc Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
JP7474709B2 (ja) 2018-02-27 2024-04-25 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
JP7698418B2 (ja) * 2018-03-13 2025-06-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｅｇｆｒ活性化変異を有するがんを治療するための方法
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
CN120817904A (zh) 2018-08-24 2025-10-21 法码科思莫斯有限公司 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
JP7598642B2 (ja) * 2018-10-12 2024-12-12 ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ ネブラスカ ホスホジエステラーゼ阻害剤
CN111100128B (zh) * 2018-10-26 2022-09-06 广安凯特制药有限公司 一种瑞博西尼中间产品的合成方法及其中间体化合物
EP3902805A4 (en) * 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
CN114040764A (zh) 2019-02-15 2022-02-11 因赛特公司 细胞周期素依赖性激酶2生物标记物及其用途
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US20220296595A1 (en) 2019-05-05 2022-09-22 Qilu Regor Therapeutics Inc. Cdk inhibitors
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022543062A (ja) 2019-08-01 2022-10-07 インサイト・コーポレイション Ｉｄｏ阻害剤の投与レジメン
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
MX2022012780A (es) 2020-04-16 2023-01-18 Incyte Corp Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
ES3048084T3 (en) 2020-05-19 2025-12-09 Pharmacosmos Holding As Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023283213A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
EP4370515A1 (en) 2021-07-14 2024-05-22 Incyte Corporation Tricyclic compounds as inhibitors of kras
TW202320795A (zh) 2021-07-26 2023-06-01 美商凱爾科迪股份有限公司 使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
WO2023036252A1 (zh) * 2021-09-08 2023-03-16 希格生科（深圳）有限公司 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
MX2024004444A (es) 2021-10-14 2024-05-08 Incyte Corp Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
KR20240122783A (ko) 2021-11-22 2024-08-13 인사이트 코포레이션 Fgfr 저해제 및 kras 저해제를 포함하는 병용 요법
WO2023102184A1 (en) 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US20230192722A1 (en) 2021-12-22 2023-06-22 Incyte Corporation Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
JP2025512710A (ja) 2022-03-07 2025-04-22 インサイト・コーポレイション Ｃｄｋ２阻害剤の固体形態、塩、ならびに調製プロセス
WO2023213271A1 (en) * 2022-05-05 2023-11-09 Beigene , Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
TW202413359A (zh) 2022-06-22 2024-04-01 美商英塞特公司 雙環胺ｃｄｋ１２抑制劑
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
EP4561991A1 (en) * 2022-07-25 2025-06-04 Cayman Chemical Company, Inc. Novel heterocycles as spla2-x inhibitors
EP4561552A2 (en) * 2022-07-29 2025-06-04 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
WO2024220532A1 (en) 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors
US20240368156A1 (en) 2023-04-18 2024-11-07 Incyte Corporation 2-azabicyclo[2.2.1]heptane kras inhibitors
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
US20250163079A1 (en) 2023-11-01 2025-05-22 Incyte Corporation Kras inhibitors
US20250195536A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
BR0308232A (pt) 2002-03-07 2004-12-28 Hoffmann La Roche Inibidores de cinase p38 de piridina e pirimidina bicìclicas
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
CN101723891A (zh) 2003-02-10 2010-06-09 沃泰克斯药物股份有限公司 通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法
AP2006003559A0 (en) 2003-09-05 2006-04-30 Neurogen Corp Ventis Pharmaceuticals Inc Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
MXPA06005578A (es) 2003-11-17 2006-08-11 Pfizer Prod Inc Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
AR049769A1 (es) * 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
EP1713806B1 (en) 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2007526906A (ja) 2004-03-05 2007-09-20 大正製薬株式会社 ピロロピリミジン誘導体
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
US20080167309A1 (en) 2004-07-22 2008-07-10 Astex Therapeutics, Ltd. Pharmaceutical Compounds
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
KR20070085286A (ko) 2004-10-29 2007-08-27 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 바이사이클릭 피리미딘 유도체
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2006074985A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
WO2006137769A1 (en) 2005-06-20 2006-12-28 Astrazeneca Ab Process for the preparation of 3,7-dihydroxy-1,5-diazacyclooctanes
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US20070225304A1 (en) 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
GB0520164D0 (en) 2005-10-04 2005-11-09 Novartis Ag Organic compounds
WO2007040280A1 (ja) 2005-10-06 2007-04-12 Nippon Soda Co., Ltd. 環状アミン化合物および有害生物防除剤
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
BRPI0620151A2 (pt) 2005-12-22 2010-06-29 Wyeth Corp composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo
BRPI0709007A2 (pt) 2006-03-09 2011-06-21 Pharmacopeia Inc inibidores de 8-heteroarilpurina mnk2 para tratamento de distúrbios metabólicos
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
ATE533771T1 (de) 2007-11-20 2011-12-15 Bristol Myers Squibb Co Cyclopropylkondensierte indolobenzazepine als hcv-ns5b-inhibitoren
MX2010006457A (es) 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
CA2714177A1 (en) * 2008-02-06 2009-08-13 Novartis Ag Pyrrolo [2,3-d] pyridines and use thereof as tyrosine kinase inhibitors
WO2009115084A2 (de) 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
CN102186856B (zh) 2008-08-22 2014-09-24 诺华股份有限公司 作为cdk抑制剂的吡咯并嘧啶化合物
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos

Also Published As

Publication number Publication date
RS54263B1 (sr) 2016-02-29
IL221520A (en) 2015-07-30
BR112012020922B1 (pt) 2020-12-22
ECSP12012111A (es) 2012-09-28
WO2011101409A1 (en) 2011-08-25
US20130150342A1 (en) 2013-06-13
NI201200135A (es) 2012-10-30
AR080198A1 (es) 2012-03-21
MX2012009613A (es) 2012-09-12
CN102918043B (zh) 2015-07-29
HRP20151071T1 (hr) 2015-11-06
JP2013519707A (ja) 2013-05-30
HN2012001744A (es) 2015-08-24
TN2012000413A1 (en) 2014-01-30
DOP2012000225A (es) 2013-01-15
AU2011217286B2 (en) 2014-06-19
CL2012002270A1 (es) 2012-10-26
ES2548532T3 (es) 2015-10-19
UY33227A (es) 2011-09-30
KR20130006625A (ko) 2013-01-17
CN102918043A (zh) 2013-02-06
JP5788415B2 (ja) 2015-09-30
US9309252B2 (en) 2016-04-12
MA34066B1 (fr) 2013-03-05
ZA201206079B (en) 2013-05-29
PE20121815A1 (es) 2013-02-03
US8957074B2 (en) 2015-02-17
HK1176616A1 (en) 2013-08-02
DK2536730T3 (en) 2015-09-28
EP2536730A1 (en) 2012-12-26
TW201130848A (en) 2011-09-16
TWI503322B (zh) 2015-10-11
UA108369C2 (uk) 2015-04-27
SG183218A1 (en) 2012-09-27
CA2790637A1 (en) 2011-08-25
US20150099737A1 (en) 2015-04-09
EA022355B1 (ru) 2015-12-30
GEP20146146B (en) 2014-08-25
CA2790637C (en) 2018-04-10
SI2536730T1 (sl) 2015-10-30
EA201201161A1 (ru) 2013-03-29
PT2536730E (pt) 2015-10-29
EP2536730B1 (en) 2015-07-08
KR101812357B1 (ko) 2017-12-26
PH12012501649A1 (en) 2018-02-07
PL2536730T3 (pl) 2015-12-31
AU2011217286A1 (en) 2012-08-30
NZ601754A (en) 2014-04-30
BR112012020922A2 (pt) 2016-05-03
SMT201500265B (it) 2016-01-08

Similar Documents

Publication Publication Date Title
ME02202B (me) Jedinjenja pirolopirimidina kao inhibitori cdk4/6
JP2013519707A5 (me)
AU2015296322B2 (en) 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
KR101787680B1 (ko) 키나아제 억제제 및 이의 용도
AU2012339499B2 (en) Aminoquinazoline derivatives and their salts and methods of use
JP2024517693A (ja) ２－アミノベンゾチアゾール化合物及びその使用方法
JP2024532733A (ja) 複素環式化合物及び使用方法
ME02635B (me) Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
BR112020022201A2 (pt) análogos de rapamicina ligada a c40, c28, e c-32 como inibidores de mtor
DK2655375T3 (en) PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
JP2017222709A5 (me)
JP2015511245A5 (me)
JP2019535664A5 (me)
JP2013500975A5 (me)
NZ610018A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JP2015508075A5 (me)
JP2012528828A5 (me)
JP2020527174A5 (me)
JP2023549055A (ja) 複素環式スピロ化合物及びその使用方法
ME02922B (me) Novi derivati indolizina, postupak njihove proizvodnje i farmaceutske kompozicije koje ih sadrže
US12006320B2 (en) Heterocyclic derivatives as PI3K inhibitors
RU2014109748A (ru) Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor
AU2021373162A1 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
CN112867715A (zh) 作为腺苷受体拮抗剂的5-氮杂吲唑衍生物
RU2023134860A (ru) Ингибиторы мутации her2